{
    "nctId": "NCT02190227",
    "briefTitle": "RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment",
    "officialTitle": "Tumor RNA Disruption Assay as a Tool to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer: Optimizing Timing of Biopsy",
    "overallStatus": "COMPLETED",
    "conditions": "Invasive Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Pathologic complete response (pCR).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be female.\n* Patients must be 18 years of age or older.\n* Patients with stage I, II, or III breast cancer that is greater or equal to 2 cm on clinical examination.\n* Patients that have biopsy proven invasive breast cancer diagnosed by core needle biopsy\n* Patients who are chemotherapy and radiotherapy na\u00efve for the treatment of the current breast cancer.\n* Patients that accept to undergo neoadjuvant chemotherapy.\n* Patients with bilateral breast cancer are eligible.\n* Patients that understand, accept, and have signed the approved written consent form.\n* Patients will need to consent to be part of the study.\n\nExclusion Criteria:\n\nPatients with one or more of the following conditions are ineligible for this study:\n\n* Patients who have had previous surgery, chemotherapy or radiotherapy for the current breast cancer\n* Patients who are pregnant or breast feeding.\n* Psychiatric or addictive disorders or conditions or social factors that may preclude the patient from meeting study requirements.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}